<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669172</url>
  </required_header>
  <id_info>
    <org_study_id>EC-HEM-HGUGM-2016-01</org_study_id>
    <nct_id>NCT03669172</nct_id>
  </id_info>
  <brief_title>Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia</brief_title>
  <official_title>Fase I/II, Unicentric, Historical Control Clinical Trial to Evaluate the Effectiveness of Donor IL-15 Stimulated NK Cells Post Transplant Infusion, in Acute Leukemia Patients With Poor Prognosis and Haploidentical Unmanipulated Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martín, José Luis Díez, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martín, José Luis Díez, M.D.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial phase I and II, single-center, historical control, to evaluate the
      effectiveness of donor IL-15 stimulated NK cells post transplant infusion, in acute leukemia
      patients with poor prognosis and haploidentical unmanipulated transplant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial wants to study the safety, effectiveness and efficacy of NK cells
      incubated infusion (CD56 +, CD3) incubated ex vivo with IL-15 infusion in patients with high
      risk acute myeloid leukemia undergoing allogeneic transplant of an haploidentical donor with
      post-transplant cyclophosphamide administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Up to 2 years after first infusion</time_frame>
    <description>Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reevaluation of the Minimal residual disease (MRD)</measure>
    <time_frame>Up to 1 year after first infusion</time_frame>
    <description>Reevaluation of the Minimal residual disease (MRD) in bone marrow by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>ACUTE LEUKEMIA</condition>
  <arm_group>
    <arm_group_label>NK cells infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor IL-15 stimulated NK cells infusion</intervention_name>
    <description>DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT</description>
    <arm_group_label>NK cells infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than 18 years old, with acute myeloid leukemia who goes to undergo haploidentical

          2. Assessable disease by analytic, molecular or image techniques.

          3. Comorbidity Sorror index less than 6.

          4. Give informed consent according to the legal requirements.

          5. Dispose of a donor without exclusion criteria.

        Exclusion Criteria:

          1. Positive HIV serology.

          2. Patients with an active infection or other underlying serious medical statement.

          3. Any medical process, analytical abnormality or important psychiatric disorder,
             according to the investigator's opinion, that prevent the participation of the patient
             in the study.

          4. Participation of any other interventional clincal trial within 30 days of planned
             enrollment into this study.

          5. Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yago Parga Cunqueiro</last_name>
    <phone>+34695597268</phone>
    <email>yago.parga@ypsilon.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Pérez Corral</last_name>
    <email>apcorral@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Muñoz Martínez</last_name>
      <email>cmunozmartinez@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Nieves Dorado Herrero</last_name>
      <email>nieves.dorado@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>José Luís Diéz Martín</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

